Thought I'd create this board and see if anybody out there is watching this stock.
NiCord product looks good in terms of science and market potential. Science is remarkably simple and cheap, making for very good potential returns. Process is simple too, they nicely fit themselves into the current treatment paradigm. Funds seem to be able to maybe get them to Phase III data within the next 12 months.
Based on their last call, partnering is not in the cards, and I feel is unnecessary for them to complete the trial and to for distribution to the relevant US/European transplant centres.
I'll wait for the share price to go down as they burn through their cash, and potentially go for a raise but even where it stands now at a M/C of circa 200 million seems pretty decent already.